Richardson Electronics (RELL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Aug, 2026Executive summary
Annual Meeting scheduled for October 6, 2026, to elect seven directors, ratify the auditor, and approve executive compensation on an advisory basis.
Proxy materials are distributed electronically, with voting available by phone, internet, or mail.
Only stockholders of record as of August 7, 2026, are entitled to vote.
Voting matters and shareholder proposals
Proposals include election of seven directors, ratification of BDO USA, P.C. as auditor for fiscal 2027, and advisory approval of executive compensation.
Board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be received by April 23, 2027.
Board of directors and corporate governance
Board consists of seven nominees with diverse industry, management, and financial expertise.
Five directors are independent per Nasdaq standards; Mr. Richardson serves as both Chairman and CEO.
Mr. Plante serves as lead independent director; non-management directors meet in executive sessions.
Four standing committees: Audit, Compensation & Governance, Executive, and Nominating.
Non-employee directors receive restricted stock awards, retainers, and meeting fees; required to maintain $150,000 stock ownership by August 1, 2027.
Latest events from Richardson Electronics
- Director elections, auditor ratification, and executive pay are up for vote at the annual meeting.RELL
Proxy filing - Q4 net sales up 27.6%, net income $6.4M, record backlog, and strong FY27 outlook.RELL
Q4 2026 - Q3 FY26 delivered 3.1% sales growth, profitability, and record backlog, led by PMT segment gains.RELL
Q3 2026 - Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, backlog $135.7M, $0.06 dividend, no debt.RELL
Q2 2026 - Q1 FY2026 net income tripled to $1.9M on 1.6% sales growth and improved margins.RELL
Q1 2026 - Q1 FY25 sales up 2.2% to $53.7M, with strong GES and Healthcare growth and a $137.4M backlog.RELL
Q1 2025 - Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 2024 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 2025 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 2025